Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 397

1.

Development and clinical use of prasugrel and ticagrelor.

Ahmad S, Storey RF.

Curr Pharm Des. 2012;18(33):5240-60. Review.

PMID:
22724412
2.

New anti-platelet agents: the end of resistance?

Kastrati A.

Thromb Res. 2012 Oct;130 Suppl 1:S53-5. doi: 10.1016/j.thromres.2012.08.275. Review.

PMID:
23026663
3.

New antiplatelet agents in the treatment of acute coronary syndromes.

Sabouret P, Taiel-Sartral M.

Arch Cardiovasc Dis. 2014 Mar;107(3):178-87. doi: 10.1016/j.acvd.2014.01.009. Epub 2014 Mar 11. Review.

4.

Third generation P2Y12 antagonists inhibit platelet aggregation more effectively than clopidogrel in a myocardial infarction registry.

Olivier CB, Diehl P, Schnabel K, Weik P, Zhou Q, Bode C, Moser M.

Thromb Haemost. 2014 Feb;111(2):266-72. doi: 10.1160/TH13-06-0508. Epub 2013 Oct 31.

PMID:
24172891
5.

Clinical use of clopidogrel.

Sarafoff N, Byrne RA, Sibbing D.

Curr Pharm Des. 2012;18(33):5224-39. Review.

PMID:
22724411
6.

Impact of clopidogrel and potent P2Y 12 -inhibitors on mortality and stroke in patients with acute coronary syndrome or undergoing percutaneous coronary intervention: a systematic review and meta-analysis.

Aradi D, Komócsi A, Vorobcsuk A, Serebruany VL.

Thromb Haemost. 2013 Jan;109(1):93-101. doi: 10.1160/TH12-06-0377. Epub 2012 Nov 29. Review.

PMID:
23197191
7.

Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction.

Alexopoulos D, Xanthopoulou I, Gkizas V, Kassimis G, Theodoropoulos KC, Makris G, Koutsogiannis N, Damelou A, Tsigkas G, Davlouros P, Hahalis G.

Circ Cardiovasc Interv. 2012 Dec;5(6):797-804. doi: 10.1161/CIRCINTERVENTIONS.112.972323. Epub 2012 Nov 20.

8.

ADP-receptor inhibitors in the perioperative period: the good, the bad, and the ugly.

Oprea AD, Popescu WM.

J Cardiothorac Vasc Anesth. 2013 Aug;27(4):779-95. doi: 10.1053/j.jvca.2012.11.014. Epub 2013 May 3. Review. No abstract available.

PMID:
23648080
9.

[Differentiated antiplatelet therapy for acute coronary syndromes].

Schäfer A, Arntz HR, Boudriot E, Garlichs C, Hoffmann S, Ince H, Klingenheben T, Weil J, Zugck C, Helms TM, Silber S.

Dtsch Med Wochenschr. 2014 Jan;139(4):152-8. doi: 10.1055/s-0033-1359911. Epub 2014 Jan 15. Review. German.

PMID:
24430955
10.

[Prasugrel for acute and long-term treatment of patients with acute coronary syndromes: what is state-of-the-art?].

Silber S, Helms TM, Garlichs C, Arntz HR, Weil J, Ince H, Klingenheben T, Hoffmann S, Boudriot E, Steiger H, Zugck C.

Dtsch Med Wochenschr. 2011 Apr;136(15):782-5. doi: 10.1055/s-0031-1272567. Epub 2011 Mar 22. Review. German. No abstract available.

PMID:
21432747
11.

Ticagrelor--a new platelet aggregation inhibitor in patients with acute coronary syndromes. An improvement of other inhibitors?

Kowalczyk M, Banach M, Mikhailidis DP, Hannam S, Rysz J.

Med Sci Monit. 2009 Dec;15(12):MS24-30. Review.

PMID:
19946242
12.

Platelet adenosine diphosphate receptor antagonists: ticlopidine to ticagrelor-a long continuing journey.

Kaul U, Mansoor AH.

Indian Heart J. 2012 Jan-Feb;64(1):54-9. doi: 10.1016/S0019-4832(12)60012-1. Epub 2012 Mar 26. Review.

13.

Relationship between post-treatment platelet reactivity and ischemic and bleeding events at 1-year follow-up in patients receiving prasugrel.

Bonello L, Mancini J, Pansieri M, Maillard L, Rossi P, Collet F, Jouve B, Wittenberg O, Laine M, Michelet P, Bessereau J, Lemesle G, Dignat-George F, Paganelli F, Camoin-Jau L.

J Thromb Haemost. 2012 Oct;10(10):1999-2005. doi: 10.1111/j.1538-7836.2012.04875.x.

14.

Pretreatment platelet reactivity contribution to residual, post-treatment platelet reactivity in prasugrel-treated and ticagrelor-treated patients.

Alexopoulos D, Xanthopoulou I, Davlouros P, Tsigkas G, Damelou A, Theodoropoulos KC, Gkizas V, Hahalis G.

J Thromb Haemost. 2013 Feb;11(2):381-4. doi: 10.1111/jth.12095. No abstract available.

15.
16.

Tailoring antiplatelet therapy: a step toward individualized therapy to improve clinical outcome?

Laine M, Camoin-Jau L, Bessereau J, Sébastien A, Paganelli F, Bonello L.

Curr Pharm Des. 2012;18(33):5392-401. Review.

PMID:
22724420
17.

Emerging oral antiplatelet therapies for acute coronary syndromes.

Pollack CV Jr.

Hosp Pract (1995). 2010 Nov;38(4):29-37. doi: 10.3810/hp.2010.11.337.

PMID:
21068524
18.

Prasugrel vs clopidogrel in cardiogenic shock patients undergoing primary PCI for acute myocardial infarction. Results of the ISAR-SHOCK registry.

Orban M, Mayer K, Morath T, Bernlochner I, Hadamitzky M, Braun S, Schulz S, Hoppmann P, Hausleiter J, Tiroch K, Mehilli J, Schunkert H, Massberg S, Laugwitz KL, Sibbing D, Kastrati A.

Thromb Haemost. 2014 Dec;112(6):1190-7. doi: 10.1160/TH14-06-0489. Epub 2014 Aug 28.

PMID:
25183544
19.

Cost-effectiveness of universal and platelet reactivity assay-driven antiplatelet therapy in acute coronary syndrome.

Coleman CI, Limone BL.

Am J Cardiol. 2013 Aug 1;112(3):355-62. doi: 10.1016/j.amjcard.2013.03.036. Epub 2013 Apr 27.

PMID:
23631863
20.

A model-based analysis of the clinical and economic impact of personalising P2Y12-receptor inhibition with platelet function testing in acute coronary syndrome patients.

Straub N, Beivers A, Lenk E, Aradi D, Sibbing D.

Thromb Haemost. 2014 Feb;111(2):290-9. doi: 10.1160/TH13-08-0679. Epub 2013 Oct 24.

PMID:
24154566

Supplemental Content

Support Center